reasonably likely reflect clinical benefit confirmed findings milestone fight alzheimer disease says reiman leader alzheimer prevention initiative organization aimed accelerating evaluation approval therapies prevent alzheimer howard recently co authored paper raising concerns aducanumab research says not convinced biogen explanation disparate results explained small difference outcome received highest dose reasoning believe trial showed benefit instead showed howard troubled observation highest dose suffered effects people significant effects likely taking active drug versus placebo unblind study doctors know patients active drug unconsciously skew results favor says highest dose group higher dropout rate tilt results benefit drug howard says smaller remaining high dose group